11 completed. 11 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Completed 11 |
| Phase 2 | 1 | Completed 1 |
Follow CP protocol: new trials by email Literature Review of CP protocol trials Research Report on CP protocol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer Durvalumab, Placebo, Cisplatin/ Etoposide - Non-Small Cell Lung Cancer | Phase 3 | Completed | AstraZeneca | 328 | 2018-03-29 | 2026-07-14 |
| ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Chemotherapy, Rucaparib - Ovarian Cancer, Epithelial Ovarian Cancer | Phase 3 | Completed | pharmaand GmbH | 349 | 2017-03-01 | 2023-06-09 |
| Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma (Epirubicin Cisplatin 5-Fluorouracil / Xeloda) OR 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel, Carboplatin paclitaxel plus concurrent radiotherapy - Esophageal Cancer, Adenocarcinoma, Esophageal | Phase 2 / Phase 3 | Completed | Dr. Gordon Buduhan | 29 | 2015-09-01 | 2024-08-28 |
| Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy Docetaxel Cyclophosphamide, Cyclophosphamide Fluorouracil Epirubicin Docetaxel, Epirubicin Cyclophosphamide Paclitaxel - Primary Breast Cancer | Phase 3 | Completed | Fudan University | 1570 | 2010-06-01 | 2020-05-19 |
| Epirubicin or Not in Patients With TOP2A (Topoisomerase (DNA) II Alpha (170kD)) Normal Early Breast Cancer Epirubicin, cyclophosphamide and docetaxel, docetaxel, cyclophosphamide - Breast Neoplasms | Phase 3 | Completed | Danish Breast Cancer Cooperative Group | 2015 | 2008-06-01 | 2018-04-05 |
| Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC) Paclitaxel + Carboplatin, Monotherapy (gemcitabine or vinorelbine) - NSCLC | Phase 3 | Completed | Intergroupe Francophone de Cancerologie Thoracique | 451 | 2006-03-01 | 2013-10-25 |
| A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma Sorafenib (Nexavar, BAY43-9006), Carboplatin/Paclitaxel, Placebo - Melanoma | Phase 3 | Completed | Bayer | 270 | 2005-05-01 | 2014-10-31 |
| Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC) gemcitabine/Eloxatin (GEMOX), carboplatin/paclitaxel (CP) - Carcinoma, Non-Small-Cell Lung | Phase 3 | Completed | Sanofi | 383 | 2004-03-01 | 2009-04-16 |
| Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma Paclitaxel+Carboplatin - Epithelial Ovarian Cancer, Primary Peritoneal Cancer | Phase 3 | Completed | Japanese Gynecologic Oncology Group | 637 | 2003-04-01 | 2020-02-17 |
| Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer TCG, TC - Fallopian Tube Cancer, Ovarian Cancer | Phase 3 | Completed | AGO Study Group | 1742 | 2002-08-01 | 2014-06-25 |
| A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer Cisplatin+Vindesine+MMC/ concurrent radiation, Irinotecan+Carboplatin/concurrent radiation, Paclitaxel+Carboplatin/concurrent radiation - Lung Cancer | Phase 3 | Completed | West Japan Thoracic Oncology Group | 450 | 2001-04-01 | 2006-01-06 |
Carcinoma, Ovarian Epithelial (3) · Fallopian Tube Neoplasms (3) · Ovarian Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Adenocarcinoma (1) · Adenocarcinoma Of Esophagus (1) · Breast Neoplasms (1) · Carcinoma (1) · Esophageal Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1) · Recurrence (1)
AGO Study Group (1) · AstraZeneca (1) · Bayer (1) · Danish Breast Cancer Cooperative Group (1) · Dr. Gordon Buduhan (1) · Fudan University (1) · Intergroupe Francophone de Cancerologie Thoracique (1) · Japanese Gynecologic Oncology Group (1) · Sanofi (1) · West Japan Thoracic Oncology Group (1) · pharmaand GmbH (1)
Canada (3) · France (3) · United States (3) · Brazil (2) · Czechia (2) · Denmark (2) · Germany (2) · Hungary (2) · Japan (2) · Poland (2) · Russia (2) · United Kingdom (2) · Australia (1) · China (1) · India (1)
Andreas du Bois, MD, PhD (1) · Bent Ejlertsen, M.D. (1) · E. Pujade-Lauraine, MD, PhD (1) · Gordon Buduhan, MD MSc FRCSC (1) · Henning T. Mouridsen, M.D. (1) · Hisao Uejima, MD (1) · J. Herrstedt (1) · Jeffrey Bradley, MD (1) · Makoto Yasuda, M.D. (1) · Yasir Nagarwala, MD (1)
PMID 19349552, PMID 19767092, PMID 20733132, PMID 21410972, PMID 21831418, PMID 23948349, PMID 24114964, PMID 24356636, PMID 25541155, PMID 25578377, PMID 35298906, PMID 39442040, PMID 39914419
2005 (1), 2016 (1), 2017 (1)